Circadian Rhythms and Mental Health: Sleep-Wake Disruption, Light Therapy, Chronotherapy, and Mood Disorders — Mechanisms, Evidence, and Clinical Applications

The relationship between circadian rhythms and mental health extends far beyond the colloquial observation that poor sleep worsens mood. Circadian disruption is now recognized as a core pathophysiological feature of multiple psychiatric disorders — not merely a symptom or consequence, but a mechanistic contributor to disease onset, maintenance, and relapse. The master circadian pacemaker in the suprachiasmatic nucleus (SCN) of the anterior hypothalamus orchestrates approximately 24-hour oscillations in sleep-wake behavior, core body temperature, cortisol secretion, melatonin production, and neurotransmitter availability. When this system is misaligned — whether through genetic vulnerability, environmental disruption, or illness — psychiatric consequences are both predictable and measurable.

Epidemiological data consistently show that circadian rhythm sleep-wake disorders (CRSWDs) co-occur with mood disorders at rates far exceeding chance. In the general population, the prevalence of any CRSWD is estimated at 1–3%, but among individuals with major depressive disorder (MDD) or bipolar disorder (BD), estimates of clinically significant circadian disruption range from 40% to 80%, depending on the assessment method and the specific circadian parameter measured. The DSM-5-TR classifies circadian rhythm sleep-wake disorders under the sleep-wake disorders chapter (codes 307.45 / G47.2x), with subtypes including delayed sleep-wake phase disorder, advanced sleep-wake phase disorder, irregular sleep-wake rhythm disorder, non-24-hour sleep-wake rhythm disorder, shift work disorder, and jet lag disorder. However, the diagnostic framework substantially underrepresents the role of circadian disruption in psychiatric illness, which is typically embedded within mood and psychotic disorder presentations rather than diagnosed as a standalone condition.

This article provides a detailed examination of the neurobiology of circadian disruption in mental illness, the evidence base for chronotherapeutic interventions including bright light therapy (BLT), sleep deprivation (wake therapy), melatonergic agents, and social rhythm therapy, and the prognostic factors that determine who benefits most from circadian-targeted treatments.

The mammalian circadian system is built on cell-autonomous transcription-translation feedback loops (TTFLs). The core loop involves the transcription factors CLOCK and BMAL1, which heterodimerize and activate transcription of the Period (PER1, PER2, PER3) and Cryptochrome (CRY1, CRY2) genes. PER and CRY proteins accumulate, form complexes, and translocate back to the nucleus where they inhibit their own transcription by repressing the CLOCK:BMAL1 complex. This cycle takes approximately 24 hours and is fine-tuned by auxiliary loops involving REV-ERBα/β and RORα. These molecular oscillators are present in virtually every cell in the body but are synchronized — or entrained — by the SCN, which receives direct photic input from intrinsically photosensitive retinal ganglion cells (ipRGCs) expressing the photopigment melanopsin (peak sensitivity ~480 nm, blue light).

The psychiatric relevance of this system is now supported by convergent lines of evidence:

• Genetic findings: Genome-wide association studies (GWAS) have identified shared genetic loci between circadian clock genes and psychiatric disorders. Polymorphisms in CLOCK, PER2, PER3, CRY1, and TIMELESS have been associated with vulnerability to MDD, BD, and seasonal affective disorder (SAD). A gain-of-function variant in CRY1 (CRY1Δ11) causes delayed sleep phase and has been linked to mood instability. The landmark UK Biobank analysis by Lyall et al. (2018), encompassing over 91,000 participants with actigraphy data, demonstrated that lower relative amplitude of rest-activity rhythms was significantly associated with major depression (OR = 1.06 per SD decrease), bipolar disorder (OR = 1.11), mood instability, loneliness, and lower subjective well-being, even after extensive covariate adjustment.
• Monoaminergic and glutamatergic interactions: The SCN sends polysynaptic projections to the dorsal raphe nucleus (serotonin), locus coeruleus (norepinephrine), and ventral tegmental area (dopamine), meaning circadian signals directly modulate the neurotransmitter systems most implicated in mood disorders. Serotonin synthesis is under circadian control via rhythmic expression of tryptophan hydroxylase 2 (TPH2). Dopamine transporter (DAT) expression and dopamine receptor sensitivity show robust circadian oscillations, providing a mechanistic link between circadian disruption and the reward system dysfunction observed in depression and mania.
• HPA axis dysregulation: Cortisol follows a tight circadian rhythm with a morning peak (cortisol awakening response, CAR) and evening nadir. In MDD, the CAR is often blunted and the evening nadir is elevated, reflecting both HPA axis hyperactivity and circadian flattening. In BD, manic episodes are associated with phase-advanced cortisol rhythms, while depressive episodes show phase delays.
• Melatonin system: Melatonin, secreted by the pineal gland under SCN control and suppressed by light, serves as the primary hormonal signal of darkness. Dim-light melatonin onset (DLMO) is the gold-standard biomarker of circadian phase. Patients with MDD show blunted melatonin amplitude, while patients with seasonal affective disorder show phase-delayed DLMO relative to their sleep timing — a finding that forms the basis of the phase-shift hypothesis proposed by Lewy et al.
• Neuroinflammatory pathways: The molecular clock regulates NF-κB signaling, cytokine production, and microglial activation. Circadian disruption — as seen in shift workers — leads to elevated IL-6, TNF-α, and C-reactive protein levels, all of which are independently associated with depression risk. This positions circadian disruption as a potential mediating variable in the inflammation-depression link.

Circadian disruption manifests differently across mood disorder subtypes, and recognizing these patterns has both diagnostic and therapeutic implications.

Major Depressive Disorder (MDD)

The most consistent circadian findings in MDD are phase delay (later-than-normal timing of sleep, temperature, and melatonin rhythms), reduced circadian amplitude (flattened rest-activity cycles), and disrupted sleep architecture (shortened REM latency, increased REM density, reduced slow-wave sleep). The observation that REM sleep abnormalities in depression are state-dependent but partially trait-like led to early models of depression as a circadian phase disturbance. Approximately 60–80% of patients with MDD report insomnia, and 15–30% report hypersomnia. Hypersomnic depression is particularly associated with circadian features — later chronotype, greater phase delay, and atypical symptom features including leaden paralysis and mood reactivity.

Bipolar Disorder (BD)

Circadian disruption in BD is arguably more pronounced and more central to pathophysiology than in any other psychiatric condition. Mania is characterized by dramatically reduced sleep need (not just insomnia — patients feel rested after 2–3 hours), phase advance, and increased rest-activity amplitude. Bipolar depression shows the opposite pattern: hypersomnia, phase delay, and reduced amplitude. Critically, sleep disruption is both a prodrome and a trigger of manic episodes. The social zeitgeber theory, formalized by Ehlers, Frank, and Kupfer, posits that life events disrupt social routines, which in turn disrupt circadian rhythms, which then precipitate mood episodes in vulnerable individuals. This model directly informs interpersonal and social rhythm therapy (IPSRT).

Studies using actigraphy demonstrate that interepisode BD patients still show greater rest-activity rhythm fragmentation, higher intradaily variability, and lower interdaily stability compared to healthy controls, suggesting trait-level circadian dysfunction. Prevalence of delayed sleep-wake phase disorder is estimated at 10–30% among BD patients versus ~1–3% in the general population.

Seasonal Affective Disorder (SAD)

SAD (DSM-5-TR specifier: "with seasonal pattern") affects an estimated 1–6% of the population in temperate latitudes, with a clear latitude gradient: prevalence increases from approximately 1.4% at latitudes around 28°N to 9.7% at 64°N (Magnusson & Stefansson, 1993). The phase-shift hypothesis of SAD proposes that the circadian pacemaker becomes phase-delayed relative to the sleep-wake cycle as photoperiod shortens in autumn and winter. Lewy et al. demonstrated that morning bright light (which phase-advances the circadian clock) is superior to evening bright light (which phase-delays) in treating SAD, and that the magnitude of phase correction correlates with the magnitude of mood improvement — supporting a causal rather than merely correlational relationship.

Diagnostic Pitfalls

Several diagnostic challenges are clinically significant:

• Circadian vs. primary insomnia: A patient with delayed sleep-wake phase disorder who is forced to wake early for work will present with sleep-onset insomnia and excessive daytime sleepiness — easily misdiagnosed as primary insomnia or depression-related insomnia. Treatment with standard hypnotics addresses neither the circadian misalignment nor the depressive consequences.
• Bipolar II misdiagnosis: Patients with severe circadian disruption, cycling between hypersomnia and short-sleep periods with increased energy, may be misdiagnosed as BD-II when the primary pathology is circadian. Detailed sleep-wake logs and actigraphy are essential for differentiation.
• Comorbid sleep apnea: Obstructive sleep apnea (OSA) affects approximately 20–40% of patients with MDD and is more prevalent in BD. OSA fragments sleep architecture and disrupts circadian alignment, and its treatment with CPAP can independently improve mood symptoms. Failure to screen for OSA in treatment-resistant depression is a significant clinical error.

Bright light therapy (BLT) is the oldest and best-studied chronotherapeutic intervention. The standard protocol involves exposure to a broad-spectrum white light source delivering 10,000 lux at eye level for 30 minutes, administered in the early morning (typically within 30 minutes of habitual wake time). The mechanism involves activation of melanopsin-expressing ipRGCs, which project via the retinohypothalamic tract to the SCN, producing a phase advance of the circadian clock, suppression of melatonin, and downstream modulation of monoaminergic neurotransmission.

Efficacy in Seasonal Affective Disorder

BLT is the first-line treatment for SAD. A Cochrane-quality meta-analysis by Golden et al. (2005) found a pooled effect size (Cohen's d) of 0.84 for BLT versus control conditions in SAD — a large effect. Response rates in clinical trials range from 50–80%, with remission rates of 40–60%. The number needed to treat (NNT) is approximately 3–4. Onset of action is rapid — significant mood improvement typically occurs within 3–5 days, faster than any antidepressant medication.

Efficacy in Non-Seasonal Depression (MDD)

The landmark study by Lam et al. (2016), published in JAMA Psychiatry, was an 8-week, randomized, double-blind, placebo-controlled trial comparing BLT alone, fluoxetine 20 mg alone, combination BLT + fluoxetine, and a double placebo (inactive ion generator + pill placebo) in patients with non-seasonal MDD. Results demonstrated that combination BLT + fluoxetine achieved the highest response (76%) and remission rates (59%), followed by BLT monotherapy (response 50%, remission 44%), which outperformed fluoxetine monotherapy (response 29%, remission 19%). The effect size for BLT monotherapy versus placebo was d = 0.63. This study fundamentally changed the evidence landscape by establishing BLT as effective in non-seasonal depression — not just SAD.

A subsequent meta-analysis by Perera et al. (2016) in JAMA Psychiatry, encompassing 20 RCTs and over 600 patients, confirmed a pooled effect size of d = 0.41 (moderate) for BLT in non-seasonal depression, with stronger effects when used as adjunctive therapy.

Bipolar Depression: Efficacy and Safety

Sit et al. (2018) conducted a landmark 6-week RCT of midday bright light (7,000 lux) versus dim red placebo light in bipolar depression, with all participants on stable mood stabilizer regimens. Midday BLT achieved a remission rate of 68.2% compared to 22.2% in the placebo group — a striking difference with NNT ≈ 2. Critically, midday timing was chosen to minimize the risk of manic switch, which had been observed in earlier trials of morning BLT in BD. No treatment-emergent mania or hypomania occurred in the BLT group.

Comparative Positioning

Compared to first-line antidepressants, BLT demonstrates comparable or superior effect sizes for mild-to-moderate depression, faster onset of action, minimal side effects (transient headache, eye strain in <10% of patients), no drug interactions, and no withdrawal effects. However, adherence can be challenging, the placebo response in light therapy trials is complicated by the difficulty of blinding, and evidence for severe, melancholic depression as monotherapy is limited.

Total sleep deprivation (TSD), or wake therapy, is one of the most robust — and most underutilized — rapid-acting antidepressant interventions in psychiatry. In total sleep deprivation, patients remain awake for 36 consecutive hours (i.e., from morning of Day 1 through the night until evening of Day 2). In partial sleep deprivation (PSD), patients sleep from the evening until approximately 1:00–2:00 AM, then remain awake until the following evening.

Efficacy Data

A meta-analysis by Boland et al. (2017), published in the Journal of Clinical Psychiatry, encompassed 66 studies and over 2,000 patients and found that TSD produces a next-day response rate of approximately 50% across unipolar and bipolar depression. This response is rapid (within hours), clinically significant, and independent of medication status. The effect size across studies is approximately d = 0.6–0.8. The response rate in bipolar depression is particularly notable — approximately 50–65%, which is comparable to or higher than rates for pharmacological antidepressants in BD.

The critical limitation of wake therapy is that 50–80% of responders relapse after a single night of recovery sleep. This has driven the development of combination chronotherapy protocols.

Triple Chronotherapy

The triple chronotherapy (TCT) protocol combines: (1) one night of total sleep deprivation, (2) a sleep phase advance schedule over 3 days (gradually shifting bedtime from early evening [e.g., 6:00 PM] to normal timing), and (3) morning bright light therapy. This protocol, studied extensively by the groups of Benedetti and Wirz-Justice, produces sustained response rates of 50–70% at one week, with remission rates of approximately 40–50%. A study by Sahlem et al. (2014) demonstrated that TCT combined with ongoing antidepressant medication maintained response at 4 weeks in approximately 60% of patients.

The neurobiological basis of wake therapy's antidepressant effect is not fully elucidated but involves: (1) enhanced synaptic potentiation and increased adenosine accumulation, which reset homeostatic sleep pressure; (2) normalization of hyperactive anterior cingulate cortex (ACC) and amygdala reactivity; (3) increased dopaminergic transmission in the ventral striatum — PET imaging studies show that TSD increases striatal dopamine receptor availability; and (4) changes in glutamatergic signaling that parallel those seen with ketamine, suggesting possible shared downstream mechanisms between these two rapid-acting antidepressant modalities.

Pharmacological manipulation of the circadian system primarily targets the melatonin system, though other agents (lithium, valproate, GSK-3β inhibitors) have significant chronobiological effects.

Exogenous Melatonin

Exogenous melatonin (0.5–5 mg) administered 2–5 hours before DLMO can advance the circadian clock by 1–2 hours. It is first-line for delayed sleep-wake phase disorder and is useful as an adjunct in mood disorders where phase delay is documented. However, melatonin has minimal direct antidepressant properties. A meta-analysis by Ferracioli-Oda et al. (2013) found that melatonin significantly reduces sleep-onset latency (by approximately 7 minutes) and increases total sleep time (by approximately 8 minutes), with modest effect sizes. Its primary psychiatric utility is circadian realignment rather than mood modulation per se.

Ramelteon

Ramelteon is a selective MT1/MT2 melatonin receptor agonist approved for insomnia characterized by difficulty with sleep onset. It has a half-life of 1–2.6 hours and high receptor affinity (6–16x greater than melatonin for MT1). Some evidence suggests utility in bipolar disorder for stabilizing sleep-wake cycles and potentially reducing relapse, but large-scale mood disorder trials are lacking.

Agomelatine

Agomelatine is an MT1/MT2 agonist and 5-HT2C antagonist that represents the most direct pharmacological translation of circadian science into antidepressant treatment. It is approved in the European Union (not the US) for MDD. The dual mechanism is theoretically appealing: melatonin receptor agonism resynchronizes circadian rhythms, while 5-HT2C antagonism increases prefrontal dopamine and norepinephrine release. Meta-analyses show that agomelatine is superior to placebo with effect sizes of approximately d = 0.24–0.39 for depression — comparable to other antidepressants. The Kennedy et al. (2014) meta-analysis demonstrated that agomelatine has superior tolerability to SSRIs and SNRIs, with lower rates of sexual dysfunction, weight gain, and discontinuation symptoms. Response rates in clinical trials range from 49–61%, with remission rates of 27–46%. However, it requires monitoring of liver function tests due to rare hepatotoxicity (elevated transaminases in ~1% of patients).

Lithium as a Chronobiological Agent

Lithium is a direct inhibitor of glycogen synthase kinase 3β (GSK-3β), a kinase that phosphorylates and destabilizes core clock proteins including PER2, REV-ERBα, and CRY2. By inhibiting GSK-3β, lithium lengthens the circadian period, stabilizes clock gene expression, and robustly modulates circadian amplitude. This provides a mechanistic framework for lithium's mood-stabilizing properties that goes beyond its effects on inositol signaling. Lithium has been shown to normalize disrupted circadian gene expression in fibroblasts from BD patients.

Interpersonal and Social Rhythm Therapy (IPSRT), developed by Ellen Frank and colleagues at the University of Pittsburgh, is a manualized psychotherapy that directly targets circadian rhythm stabilization through behavioral regulation of social routines. It is built on the social zeitgeber theory and combines interpersonal psychotherapy (IPT) techniques with structured monitoring of five daily social rhythms: time of rising, first interpersonal contact, starting work/school, dinner, and going to bed.

Evidence Base

The landmark Maintenance Therapies in Bipolar Disorder (MTBD) study by Frank et al. (2005) randomized 175 patients with BD-I to acute treatment with IPSRT or intensive clinical management (ICM), followed by maintenance randomization to the same or different modality. Key findings included: (1) patients assigned to IPSRT in the acute phase survived significantly longer without a new affective episode during maintenance (median survival not reached vs. 73 weeks for ICM during acute); (2) the mechanism was mediated by the degree of social rhythm regularity achieved, as measured by the Social Rhythm Metric (SRM); and (3) IPSRT was particularly protective against depressive recurrences.

IPSRT is now included in multiple bipolar disorder treatment guidelines (CANMAT, NICE, ISBD) as an adjunctive psychotherapy, particularly for maintenance. The Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD) found that patients receiving intensive psychotherapy (including IPSRT, CBT, or family-focused therapy) plus pharmacotherapy had higher recovery rates than those receiving pharmacotherapy with collaborative care (64.4% vs. 51.5%).

Circadian rhythm disruption is transdiagnostic, intersecting with nearly every major psychiatric and many medical conditions.

Psychiatric Comorbidities

• Anxiety disorders: Approximately 40–60% of patients with generalized anxiety disorder report significant sleep-wake disruption. Evening chronotype is associated with higher anxiety severity and panic disorder risk. The anxiolytic effect of morning light therapy has been demonstrated in several small trials with effect sizes of d = 0.4–0.6.
• ADHD: An estimated 55–75% of adults with ADHD have delayed sleep-wake phase, and the circadian delay is associated with worse executive function and inattention. Roennebert and colleagues have proposed that ADHD and delayed sleep phase may share genetic underpinnings through clock gene polymorphisms affecting dopaminergic transmission.
• Substance use disorders: Alcohol disrupts circadian gene expression in the SCN and peripheral clocks. Chronic alcohol use disorder is associated with reduced circadian amplitude and irregular melatonin secretion. During early recovery, circadian disruption predicts relapse risk.
• Schizophrenia spectrum disorders: Circadian disruption is pervasive, with 30–50% of patients with schizophrenia showing irregular sleep-wake rhythm disorder or non-24-hour patterns. Wulff et al. (2012) demonstrated that circadian disruption in schizophrenia is independent of medication effects and correlates with cognitive impairment severity.
• PTSD: Nightmares and sleep-onset insomnia in PTSD have circadian features, with disrupted cortisol rhythms (particularly blunted CAR) and phase-shifted melatonin secretion documented in multiple studies.

Medical Comorbidities

The clinical significance of circadian disruption extends beyond psychiatry. Shift workers — the most studied population with chronic circadian misalignment — show increased rates of cardiovascular disease (RR ≈ 1.2–1.4), type 2 diabetes (RR ≈ 1.1–1.4), and breast and colorectal cancer (the IARC classified shift work involving circadian disruption as a Group 2A probable carcinogen in 2019). These medical risks compound psychiatric morbidity in populations with chronic circadian disruption, including patients with treatment-resistant mood disorders.

Not all patients with mood disorders benefit equally from circadian-targeted interventions. Several prognostic factors have been identified:

• Diurnal mood variation: Patients with classic diurnal mood variation — morning worst, evening improvement — respond more robustly to wake therapy (response rate ~60% vs. ~35% in those without diurnal variation). This is thought to reflect greater circadian involvement in their depressive pathophysiology.
• Chronotype and phase angle: Patients with documented circadian phase delay (late DLMO relative to sleep onset) respond better to morning BLT. The phase angle difference (PAD) between DLMO and midsleep predicts treatment response: a larger-than-normal PAD (indicating greater phase delay) is associated with greater improvement with morning light.
• Bipolar subtype: Bipolar depression responds more consistently to wake therapy (~50–65%) than unipolar depression (~40–50%). This may reflect the greater intrinsic circadian instability in BD, making the system more responsive to phase-shifting interventions.
• Genetic markers: Emerging evidence suggests that PER3 variable-number tandem repeat (VNTR) polymorphisms influence response to light therapy. The longer allele (PER3^5/5) is associated with greater sleep homeostatic pressure and potentially greater sensitivity to sleep deprivation as an antidepressant. However, genetic predictors are not yet clinically actionable.
• Severity and melancholia: Severe, melancholic depression responds less well to BLT monotherapy but remains responsive when BLT is combined with antidepressant medication. Psychotic depression does not appear to respond to chronotherapy.
• Treatment-resistant depression (TRD): Triple chronotherapy has shown promise in TRD populations, with response rates of 40–50% even after multiple prior treatment failures. This positions chronotherapy as a valuable augmentation strategy in algorithmic care.

Poor prognostic indicators include comorbid personality disorders (particularly borderline personality disorder, where circadian rhythms are highly irregular but responsive to behavioral interventions is low), active substance use, and severe obstructive sleep apnea that is untreated.

Optimal clinical use of chronotherapy requires accurate assessment of circadian phase, amplitude, and alignment. Several tools are available:

• Dim-Light Melatonin Onset (DLMO): The gold-standard biomarker of circadian phase. Measured via serial salivary or plasma melatonin samples collected under dim light (<30 lux) conditions. DLMO typically occurs 2–3 hours before habitual sleep onset in normally entrained individuals. A DLMO occurring after midnight suggests significant phase delay. While historically limited to research settings, commercial DLMO kits are becoming more accessible.
• Actigraphy: Wrist-worn accelerometry devices provide objective, continuous measurement of rest-activity patterns over days to weeks. Key metrics include interdaily stability (IS), intradaily variability (IV), relative amplitude (RA), M10 (most active 10 hours), and L5 (least active 5 hours). Actigraphy is recommended by the American Academy of Sleep Medicine (AASM) for the assessment of CRSWDs and is increasingly used in psychiatric research and clinical trials.
• Morningness-Eveningness Questionnaire (MEQ): The Horne-Östberg MEQ is a validated 19-item self-report instrument that categorizes individuals by chronotype. Evening chronotype (low MEQ score) is consistently associated with greater depression risk, more severe depression, and poorer treatment response to standard antidepressants.
• Social Rhythm Metric (SRM): Developed for use with IPSRT, the SRM quantifies the regularity of daily social routines. Lower SRM scores (greater irregularity) predict mood episode recurrence in BD.
• Sleep diaries: Two-week prospective sleep diaries documenting bed time, sleep onset, wake time, naps, and subjective sleep quality remain essential complements to objective measures.

In clinical practice, the implementation gap for chronotherapy remains significant. A survey of psychiatrists in the UK found that fewer than 20% routinely recommended BLT, and fewer than 5% had experience with wake therapy protocols. Integration of chronotype assessment and BLT prescription into standard psychiatric care represents a significant opportunity for improving outcomes with minimal additional cost or risk.

Several emerging lines of research are reshaping the field:

• Digital phenotyping of circadian rhythms: Smartphone-based passive sensing (screen use patterns, GPS mobility, ambient light exposure) can provide continuous, ecologically valid measures of circadian behavior. Preliminary studies demonstrate that changes in digital circadian phenotype precede mood episode onset by days, offering potential for early warning systems. The NIMH-funded BiAffect study has pioneered this approach in BD.
• Circadian medicine in inpatient psychiatry: Several European centers (notably in Milan and Basel) have implemented comprehensive inpatient chronotherapy wards where lighting, meal timing, activity scheduling, and pharmacotherapy are all coordinated according to circadian principles. Benedetti et al. have published data showing that inpatient triple chronotherapy combined with lithium in bipolar depression achieves sustained remission in approximately 55–70% of patients — outcomes that rival or exceed those of standard pharmacological approaches.
• Light-dark cycle optimization: Research on controlled light exposure in hospital settings is ongoing. Standard hospital rooms deliver irregular, low-amplitude light-dark cycles that may exacerbate circadian disruption in psychiatric inpatients. Studies of high-intensity daytime lighting in psychiatric wards (e.g., the Dutch Eindhoven studies) have shown improvements in sleep quality and depression scores.
• Ketamine and circadian resetting: Emerging data suggest that subanesthetic ketamine, in addition to its rapid antidepressant effects via NMDA receptor blockade and AMPA receptor potentiation, may directly modulate circadian clock gene expression. PER2 and BMAL1 expression changes have been documented in animal models following ketamine administration, raising the possibility that ketamine's antidepressant action is partly circadian-mediated.
• Clock gene-targeted therapeutics: REV-ERBα agonists (e.g., SR9009) and CK1δ/ε inhibitors are under preclinical investigation as potential chronotherapeutic agents. These compounds directly modulate the molecular clock and have shown anxiolytic and antidepressant-like effects in animal models.

Limitations of Current Evidence

Despite promising findings, several limitations constrain the evidence base: (1) BLT trials are inherently difficult to blind, inflating placebo response estimates; (2) wake therapy studies often lack adequate control conditions; (3) much of the DLMO and actigraphy data comes from small, single-center studies; (4) the optimal timing, duration, and intensity of BLT across different clinical populations remain incompletely defined; (5) long-term outcome data for chronotherapeutic interventions beyond 8–12 weeks are sparse; and (6) most randomized trials have been conducted in predominantly White European populations, limiting generalizability across diverse racial and ethnic groups where differences in melanopsin sensitivity, melatonin metabolism, and sociocultural sleep patterns may be relevant.

The evidence base for circadian rhythm disruption as a core pathophysiological mechanism in mood disorders is now robust and multifaceted, spanning molecular genetics, neuroimaging, epidemiology, and clinical trials. The following clinical recommendations are supported by current evidence:

• Screen all patients with mood disorders for circadian disruption using chronotype questionnaires, sleep diaries, and actigraphy when available. The MEQ or Munich Chronotype Questionnaire (MCTQ) takes minutes to administer and can guide treatment selection.
• Bright light therapy should be considered a first-line adjunctive treatment for both seasonal and non-seasonal depression (10,000 lux, 30 minutes, early morning). For bipolar depression, midday timing (7,000 lux) is preferred based on the Sit et al. (2018) protocol to minimize manic switch risk.
• Wake therapy / triple chronotherapy should be available in inpatient settings for acute, severe depression — particularly bipolar depression and treatment-resistant cases. The response rate (~50%) and speed of onset (hours) position it as one of the most efficient antidepressant interventions available.
• IPSRT should be offered as an adjunctive psychotherapy in BD, with particular attention to stabilizing the five target social rhythms.
• Melatonergic agents (exogenous melatonin, ramelteon, agomelatine) are useful for circadian phase realignment but should not be relied upon as sole antidepressant treatments.
• Address comorbid sleep disorders — particularly OSA and restless legs syndrome — which independently worsen circadian disruption and treatment-resistant mood symptoms.

Circadian-targeted interventions are notable for their favorable risk-benefit profiles, low cost, and potential for combination with essentially all pharmacological and psychotherapeutic modalities. Their systematic underuse in clinical psychiatry represents a significant gap between available evidence and clinical practice.